Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

NRAS Q61

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

NRAS mutation (125)

RAS wild-type (17)

NRAS wild-type (10)

NRAS mutation + BRAF mutation (4)

FLT3 mutation + NRAS mutation (3)

NRAS Q61K + BRAF V600E (3)

NRAS exon 2 mutation (3)

NRAS exon 4 mutation (3)

EGFR mutation + NRAS Q61K (2)

NRAS G12C + BRAF mutation (2)

NRAS exon 3 mutation (2)

ARAF mutation + NRAS mutation (1)

ASXL1 mutation + NRAS mutation (1)

BRAF wild-type + NRAS wild-type (1)

DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

DNMT3A mutation + NRAS mutation (1)

EGFR exon 20 insertion + NRAS G13V + NF1 R69fs + NF1 S340fs (1)

FLT3 mutation + NRAS mutation + PTPN11 mutation (1)

FLT3-ITD mutation + ASXL1 mutation + NRAS mutation (1)

FLT3-ITD mutation + DNMT3A mutation + NRAS mutation (1)

FLT3-ITD mutation + NRAS mutation + GATA2 mutation (1)

FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

HRAS Q61L + NRAS Q61K (1)

IDH2 mutation + NRAS mutation (1)

NF1 L581Ffs*6 + KRAS A146P + NRAS Q61K + TP53 R175H + PD-L1 T290M (1)

NPM1 mutation + NRAS mutation (1)

NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

NRAS G115Efs*46 (1)

NRAS G12C + BRAF V600E + BRAF V600D (1)

NRAS G13D + BRAF V600E (1)

NRAS mutation + U2AF1 mutation (1)

SETBP1 mutation + NRAS mutation (1)

SRSF2 mutation + DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

TET2 mutation + NRAS mutation (1)

NRAS mutation (125)

RAS wild-type (17)

NRAS wild-type (10)

NRAS mutation + BRAF mutation (4)

FLT3 mutation + NRAS mutation (3)

NRAS Q61K + BRAF V600E (3)

NRAS exon 2 mutation (3)

NRAS exon 4 mutation (3)

EGFR mutation + NRAS Q61K (2)

NRAS G12C + BRAF mutation (2)

NRAS exon 3 mutation (2)

ARAF mutation + NRAS mutation (1)

ASXL1 mutation + NRAS mutation (1)

BRAF wild-type + NRAS wild-type (1)

DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

DNMT3A mutation + NRAS mutation (1)

EGFR exon 20 insertion + NRAS G13V + NF1 R69fs + NF1 S340fs (1)

FLT3 mutation + NRAS mutation + PTPN11 mutation (1)

FLT3-ITD mutation + ASXL1 mutation + NRAS mutation (1)

FLT3-ITD mutation + DNMT3A mutation + NRAS mutation (1)

FLT3-ITD mutation + NRAS mutation + GATA2 mutation (1)

FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

HRAS Q61L + NRAS Q61K (1)

IDH2 mutation + NRAS mutation (1)

NF1 L581Ffs*6 + KRAS A146P + NRAS Q61K + TP53 R175H + PD-L1 T290M (1)

NPM1 mutation + NRAS mutation (1)

NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

NRAS G115Efs*46 (1)

NRAS G12C + BRAF V600E + BRAF V600D (1)

NRAS G13D + BRAF V600E (1)

NRAS mutation + U2AF1 mutation (1)

SETBP1 mutation + NRAS mutation (1)

SRSF2 mutation + DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

TET2 mutation + NRAS mutation (1)

›

NRAS Q61	Colorectal Cancer	NRAS Q61	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
NRAS Q61	Colorectal Cancer	NRAS Q61	Colorectal Cancer	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1
NRAS Q61	Melanoma	NRAS Q61	Melanoma	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3
NRAS Q61	Colorectal Cancer	NRAS Q61	Colorectal Cancer	binimetinib Sensitive: C3 – Early Trials binimetinib Sensitive : C3	binimetinib Sensitive: C3 – Early Trials binimetinib Sensitive : C3
NRAS Q61	Melanoma	NRAS Q61	Melanoma	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3	HL-085 Sensitive: C3 – Early Trials HL-085 Sensitive : C3
NRAS Q61	Melanoma	NRAS Q61	Melanoma	PD-0325901 + BGB-3245 Sensitive: D – Preclinical PD-0325901 + BGB-3245 Sensitive : D	PD-0325901 + BGB-3245 Sensitive: D – Preclinical PD-0325901 + BGB-3245 Sensitive : D
NRAS Q61	Melanoma	NRAS Q61	Melanoma	PD-0325901 + BGB-283 Sensitive: D – Preclinical PD-0325901 + BGB-283 Sensitive : D	PD-0325901 + BGB-283 Sensitive: D – Preclinical PD-0325901 + BGB-283 Sensitive : D
NRAS Q61	Melanoma	NRAS Q61	Melanoma	sorafenib Sensitive: D – Preclinical sorafenib Sensitive : D	sorafenib Sensitive: D – Preclinical sorafenib Sensitive : D
NRAS Q61	Cholangiocarcinoma	NRAS Q61	Cholangiocarcinoma	NXP800 Sensitive: D – Preclinical NXP800 Sensitive : D	NXP800 Sensitive: D – Preclinical NXP800 Sensitive : D
NRAS Q61	Melanoma	NRAS Q61	Melanoma	cobimetinib + roflumilast Sensitive: D – Preclinical cobimetinib + roflumilast Sensitive : D	cobimetinib + roflumilast Sensitive: D – Preclinical cobimetinib + roflumilast Sensitive : D